{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T16:12:17Z","timestamp":1744906337266},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2021,12,10]]},"DOI":"10.1038\/s41415-021-3681-9","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:02:46Z","timestamp":1639137766000},"page":"689-695","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["UK Dental Medicines Advisory Service: questions asked by dentists - part 5: prescribing for oromucosal diseases and dry mouth"],"prefix":"10.1038","volume":"231","author":[{"given":"Daniel","family":"Finn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Anne","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"3681_CR6782","unstructured":"Joint Formulary Committee. Betamethasone. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/betamethasone.html (accessed March 2020)."},{"key":"3681_CR6785","unstructured":"Joint Formulary Committee. Beclometasone Diproprionate. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/beclometasone-dipropionate.html#professionSpecificInformation (accessed February 2020)."},{"key":"3681_CR6788","unstructured":"Joint Formulary Committee. Hydrocortisone. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/hydrocortisone.html (accessed February 2020)."},{"key":"3681_CR6791","unstructured":"The British & Irish Society for Oral Medicine. Patient Information. 2020. Available at https:\/\/bisom.org.uk\/clinical-care\/patient-information\/ (accessed June 2020)."},{"key":"3681_CR6794","doi-asserted-by":"crossref","unstructured":"Randall C, Finn D J, Field E A. UK Dental Medicines Advisory Service: questions asked by dentists - part 1: prescribing regulations and medicines use. Br Dent J 2021; 231: 393-397.","DOI":"10.1038\/s41415-021-3470-5"},{"key":"3681_CR6797","unstructured":"Joint Formulary Committee. Benzydamine hydrochoride. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/benzydamine-hydrochloride.html (accessed February 2020)."},{"key":"3681_CR6800","unstructured":"Field E A, Longman L P (eds). Tyldesley's Oral Medicine. 5th ed. Oxford: Oxford University Press, 2005."},{"key":"3681_CR6802","unstructured":"Joint Formulary Committee. Doxycycline. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/doxycycline.html (accessed February 2020)."},{"key":"3681_CR6805","doi-asserted-by":"crossref","unstructured":"Rudralingam M, Randall C, Mighell A J. The use of topical steroid preparations in oral medicine in the UK. Br Dent J 2017; 223: 633-638.","DOI":"10.1038\/sj.bdj.2017.880"},{"key":"3681_CR6807","unstructured":"Marsh P, Martin M. Oral Microbiology. 5th ed. Edinburgh: Churchill Livingstone, 2009."},{"key":"3681_CR6809","doi-asserted-by":"crossref","unstructured":"Ellepola A N, Samaranayake L P. Antimycotic agents in oral candidosis: an overview: 1. Clinical variants. Dent Update 2000; 27: 111-112, 114-116.","DOI":"10.12968\/denu.2000.27.3.111"},{"key":"3681_CR6811","doi-asserted-by":"crossref","unstructured":"McIntyre G T. Oral candidosis. Dent Update 2001; 28: 132-139.","DOI":"10.12968\/denu.2001.28.3.132"},{"key":"3681_CR6814","unstructured":"Joint Formulary Committee. Nystatin. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/nystatin.html (accessed March 2020)."},{"key":"3681_CR6817","unstructured":"Joint Formulary Committee. Miconazole. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/miconazole.html (accessed February 2020)."},{"key":"3681_CR6820","unstructured":"Joint Formulary Committee. Chlorhexidine. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/chlorhexidine.html#indicationsAndDoses (accessed March 2020)."},{"key":"3681_CR6823","unstructured":"Joint Formulary Committee. Fluconazole. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/fluconazole.html (accessed February 2020)."},{"key":"3681_CR6826","unstructured":"Pfizer Limited. Summary of Product Characteristics: Diflucan 150mg hard capsules. 2019. Available at https:\/\/www.medicines.org.uk\/emc\/product\/1065\/smpc (accessed June 2020)."},{"key":"3681_CR6829","unstructured":"Joint Formulary Committee. Hydrocortisone with miconazole. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/hydrocortisone-with-miconazole.html (accessed February 2020)."},{"key":"3681_CR6832","unstructured":"Joint Formulary Committee. Topical corticosteroids. 2020. Available at https:\/\/bnf.nice.org.uk\/treatment-summary\/topical-corticosteroids.html (accessed February 2020)."},{"key":"3681_CR6835","unstructured":"Joint Formulary Committee. Fusidic Acid. 2020. Available at https:\/\/bnf.nice.org.uk\/drug\/fusidic-acid.html (accessed March 2020)."},{"key":"3681_CR6839","doi-asserted-by":"crossref","unstructured":"Dhondt F, Ninane J, De Beule K, Dhondt A, Cauwenbergh G. Oral Candidosis: treatment with absorbable and non-absorbable antifungal agents in children. Mycoses 1992; 25: 1-8.","DOI":"10.1111\/j.1439-0507.1992.tb00812.x"},{"key":"3681_CR6842","doi-asserted-by":"crossref","unstructured":"Barkvoll B, Attramadal A. Effect of nystatin and chlorhexidine digluconate on Candida albicans. Oral Surg Oral Med Oral Pathol 1989; 67: 279-281.","DOI":"10.1016\/0030-4220(89)90354-X"},{"key":"3681_CR6844","unstructured":"Black D J, Kunze K L, Wienkers L C et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-428."},{"key":"3681_CR6846","unstructured":"Medicines and Healthcare products Regulatory Agency. Topical miconazole including oral gel: reminder of potential for serious interactions with warfarin. 2016. Available at https:\/\/www.gov.uk\/drug-safety-update\/topical-miconazole-including-oral-gel-reminder-of-potential-for-serious-interactions-with-warfarin (accessed February 2020)."},{"key":"3681_CR6849","unstructured":"Scottish Dental Clinical Effectiveness Programme. Drug Prescribing for Dentistry (3rd ed). 2016. Available at http:\/\/www.sdcep.org.uk\/wp-content\/uploads\/2016\/03\/SDCEP-Drug-Prescribing-for-Dentistry-3rd-edition.pdf (accessed February 2020)."},{"key":"3681_CR6852","doi-asserted-by":"crossref","unstructured":"Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxf Med Case Reports 2018; DOI: 10.1093\/omcr\/omx104.","DOI":"10.1093\/omcr\/omx104"},{"key":"3681_CR6855","unstructured":"UK Medicines Information. Can miconazole oral gel be used by patients taking a statin? 2020. Available at https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2019\/08\/UKMi_QA_Miconazole-and-statins_update_Aug-2019.pdf (accessed February 2020)."},{"key":"3681_CR6858","doi-asserted-by":"crossref","unstructured":"Yap Y G, Camm A J. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89: 1363-1372.","DOI":"10.1136\/heart.89.11.1363"},{"key":"3681_CR6860","unstructured":"Specialist Pharmacy Service. What issues should be considered regarding drug induced QT Prolongation? 2020. Available at https:\/\/www.sps.nhs.uk\/articles\/what-issues-should-be-considered-regarding-drug-induced-qt-prolongation\/ (accessed June 2020)."},{"key":"3681_CR6863","doi-asserted-by":"crossref","unstructured":"Brown P, Fox K, Field E A, Randall C. UK Dental Medicines Advisory Service: questions asked by dentists - part 4: prescribing of high-strength fluoride toothpastes and use of fluoride varnishes in dental practice. Br Dent J 2021; 231: 623-628.","DOI":"10.1038\/s41415-021-3664-x"},{"key":"3681_CR6866","unstructured":"UK Medicines Information. What should be considered when choosing or prescribing saliva substitutes? 2020. Available at https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2020\/02\/UKMI_QA_Saliva-Subsitutes_update_June-2019-1.pdf (accessed June 2020)."},{"key":"3681_CR6870","doi-asserted-by":"crossref","unstructured":"Osailan S P R, Shirodaria S, Challacombe S J, Proctor G B. Investigating the relationship between hyposalivation and mucosal wetness. Oral Dis 2011; 17: 109-104.","DOI":"10.1111\/j.1601-0825.2010.01715.x"},{"key":"3681_CR6872","doi-asserted-by":"crossref","unstructured":"Villa A, Connell C L, Abati S. Diagnosis and management of xerostomia and hyposalivation. Ther Clin Risk Manag 2015; 11: 45-51.","DOI":"10.2147\/TCRM.S76282"},{"key":"3681_CR6875","unstructured":"Public Health England: Delivering better oral health: an evidence-based toolkit for prevention (4th ed). 2021. Available at https:\/\/www.gov.uk\/government\/publications\/delivering-better-oral-health-an-evidence-based-toolkit-for-prevention (accessed November 2021)."}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41415-021-3681-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-021-3681-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-021-3681-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:05:43Z","timestamp":1639137943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-021-3681-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,12,10]]}},"alternative-id":["3681"],"URL":"https:\/\/doi.org\/10.1038\/s41415-021-3681-9","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"assertion":[{"value":"23 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}]}}